Ginkgo Bioworks reported its financial results for the second quarter ended June 30, 2025, on August 7, 2025. The company announced the achievement of its expanded $250 million annualized cost-reduction goal three months ahead of schedule, demonstrating rigorous financial discipline.
Cell Engineering revenue for Q2 2025 increased 8.1% year-over-year to $39.134 million. However, total revenue for the quarter decreased 11.7% year-over-year to $49.604 million, primarily due to a decline in Biosecurity revenue, which fell to $10.470 million from $20.001 million in Q2 2024.
The net loss for Q2 2025 significantly improved to $(60.300) million, compared to $(217.181) million in Q2 2024. The company's cash burn was dramatically reduced to $38 million in Q2 2025. As of June 30, 2025, cash and cash equivalents stood at $203.566 million.
Ginkgo reaffirmed its full-year 2025 total revenue guidance of $167 million to $187 million. The company emphasized that its platform is proving to be a critical engine for AI in biology, with growing demand for its automation and data generation capabilities, translating into commercial traction despite overall revenue decline.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.